Medtronic suffered a shocking setback back in 2014 when its Symplicity 3 pivotal trial failed to meet its primary endpoint of reducing blood pressure meaningfully. Now it is gearing up to present new data to the FDA.

With a recent acquisition from France, Medtronic is aiming to leverage AI in the world of spine surgery and integrate the system with its robot.

In a public health crisis such as the Covid-19 pandemic, each healthcare vertical is playing […]

Our latest eBook offers examples of how some of the players in healthcare are thinking about AI, seeking to apply it across care coordination, drug development and early detection of disease and how to address some of the challenges the technology poses for adoption and implementation.

Ishrak has led the company for nearly nine years and will retire at the end of the fiscal year in late April turning over the reins to his deputy Geoff Martha who, like Ishrak, came to Medtronic from GE Healthcare.

Medtronic’s new deep brain stimulation device, Percept, reads brain signals to better optimize treatment. Traditionally, physicians adjust DBS signals based on a patient’s diary entries, which can be imprecise.

Venclose has received $27 million in Series C funding to expand market share for it venous reflux therapy. This RF ablation device is designed to simplify treatment and reduce procedure times.

Don’t mistake Stryker’s latest $500 million deal in the spine market as a simple tuck-in acquisition, says one analyst while another says it could help Stryker give Medtronic a run for its money.

After diabetes, Medtronic is looking to leverage AI through a distribution agreement with Viz.ai, which uses the technology to streamline stroke care.

The San Diego-based company has is in the midst of one of the most precipitous turnarounds in the medical device industry and is well positioned to grow alongside the expanding insulin pump market.

Medtronic announced data at the annual meeting of the American Diabetes Association on Monday that shows that people using its AI-powered Sugar.IQ diabetes assistant have better control of their blood glucose levels.

On the day that an FDA official exhorts industry to develop interoperable diabetes devices, Medtronic announces that it is teaming up with a nonprofit group to do just that.

MedCity News caught up with Omron Healthcare CEO Ranndy Kellogg at the the AdvaMed Digital MedTech Conference in San Francisco to speak about the company’s new products, emerging business lines and how collaboration with other companies have driven recent innovation.

Dexcom’s executives lay out the land in terms of competition in the standalone continuous glucose monitoring market while Medtronic CEO responds.

While the development of renal denervation technologies stalled after a failed Medtronic study in 2014, recent positive research results have led to increasing interest – and investment –  in the space.